Last reviewed · How we verify

NCT06316791

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting now EARLY_PHASE1 Last updated 10 February 2025
What this trial tests

EARLY_PHASE1 trial testing single dose of CNCT19 in Lupus Erythematosus, Systemic in 24 participants. Currently enrolling.

Timeline
14 December 2021
Primary endpoint
13 December 2025
13 December 2025

Quick facts

Lead sponsorJuventas Cell Therapy Ltd.
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment24
Start date14 December 2021
Primary completion13 December 2025
Estimated completion13 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Juventas Cell Therapy Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Lupus Erythematosus, Systemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus nephritis, immune thrombocytopenia), refractory ANCA-associated vasculitis, and refractory dermatomyositis on the basis of standard of care.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.
    Dai X, Fan Y, Zhao X. · · 2025 · cited 78× · PMID 40097390 · DOI 10.1038/s41392-025-02168-0
  2. Cutting-edge approaches to B-cell depletion in autoimmune diseases.
    Robinson WH, Fiorentino D, Chung L, Moreland LW, et al · · 2024 · cited 24× · PMID 39445025 · DOI 10.3389/fimmu.2024.1454747
  3. Application of novel CAR technologies to improve treatment of autoimmune disease.
    Cheever A, Kang CC, O'Neill KL, Weber KS. · · 2024 · cited 18× · PMID 39445021 · DOI 10.3389/fimmu.2024.1465191
  4. Current advancements in cellular immunotherapy for autoimmune disease.
    Berry CT, Frazee CS, Herman PJ, Chen S, et al · · 2025 · cited 15× · PMID 39821376 · DOI 10.1007/s00281-024-01034-5
  5. CAR immunotherapy in autoimmune diseases: promises and challenges.
    Yu J, Yang Y, Gu Z, Shi M, et al · · 2024 · cited 13× · PMID 39411714 · DOI 10.3389/fimmu.2024.1461102
  6. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
    Abdalhadi HM, Chatham WW, Alduraibi FK. · · 2024 · cited 7× · PMID 39408836 · DOI 10.3390/ijms251910511
  7. Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.
    Alsayb MA. · · 2025 · cited 2× · PMID 41041324 · DOI 10.3389/fimmu.2025.1647066
  8. Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.
    Jiang M, Zhao J, Yuan J, Yu Z, et al · · 2025 · cited 2× · PMID 40747591 · DOI 10.1080/21645515.2025.2538350

Verify or expand the search:

Other trials of single dose of CNCT19

Trials testing the same drug.

Other recruiting trials for Lupus Erythematosus, Systemic

Currently open trials in the same condition.

Other Juventas Cell Therapy Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06316791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing